Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 89 points (-0.5%) at 16,857 as of Wednesday, June 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,007 issues advancing vs. 1,935 declining with 173 unchanged. The Health Care sector currently sits up 0.4% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the sector include Grifols ( GRFS), down 1.6%, Medtronic ( MDT), down 1.1%, Valeant Pharmaceuticals International ( VRX), down 1.1%, Biogen Idec ( BIIB), down 1.0% and Novartis ( NVS), down 0.9%. Top gainers within the sector include Alnylam Pharmaceuticals ( ALNY), up 4.7%, Gilead ( GILD), up 2.2%, Cigna ( CI), up 1.7%, WellPoint ( WLP), up 1.4% and AbbVie ( ABBV), up 1.2%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. CR Bard ( BCR) is one of the companies pushing the Health Care sector lower today. As of noon trading, CR Bard is down $2.90 (-2.1%) to $138.15 on heavy volume. Thus far, 879,639 shares of CR Bard exchanged hands as compared to its average daily volume of 793,700 shares. The stock has ranged in price between $137.95-$140.99 after having opened the day at $140.98 as compared to the previous trading day's close of $141.05. C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard has a market cap of $11.3 billion and is part of the health services industry. Shares are up 5.3% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts that rate CR Bard a buy, 1 analyst rates it a sell, and 10 rate it a hold. TheStreet Ratings rates CR Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CR Bard Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.